A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment

• DOI: 10.1126/sciadv.adn8695
• Publication Date: 2024-08-28T18:01:55Z
• Authors: Shujun Feng; Yu Zhang; Chunyuan Hou; Yuta Liu; Yanfeng Gao; Yujun Song; Jun Luo
• Keywords: Male; 0301 basic medicine; Temperature; Rectum; Islet Amyloid Polypeptide; Diabetes Mellitus, Experimental; Mice; 03 medical and health sciences; Administration, Rectal; Animals; Insulin; Hypoglycemic Agents; Humans; Biomedicine and Life Sciences

Despite the therapeutic benefits of insulin-pramlintide dual-hormone therapy in diabetes, its application potential has been limited due to a lack of efficient delivery routes. Here, we developed a temperature-responsive dual-hormone foam nanoengine (HormFoam) and combined it with a customized spraying device to further construct an in situ foam-generating system for improving the rectal bioavailability of dual-hormone therapy. To support rapid clinical translation, a continuous microfluidic preparation for HormFoam was proposed, including the power unit of perfluorocarbon nanodroplets and the pharmaceutical components Pluronic F127–functionalized liposomal insulin and pramlintide. We found that HormFoam could consistently generate foams to drive drugs forward after rectal administration, which enhanced intestinal distribution and mucosa absorption, leading to systemic codelivery of insulin-pramlintide. HormFoam reproduced the physiology of endocrine pancreas for glycemic control and induced body weight loss while reversing metabolic disorders in diabetic mice with good biosafety. Therefore, HormFoam represents a state-of-the-art dual-hormone regimen with the potential to address unmet needs in diabetes management.